MG-ZG122 Humanized Monoclonal Antibody Injection

DRUG2 trials

Sponsors

Shanghai Mabgeek Biotech.Co.Ltd

Conditions

AsthmaBronchial Asthma

Phase 1

Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects

Active, not recruitingNCT05659927

Shanghai Mabgeek Biotech.Co.LtdAsthma

Start: 2023-02-09End: 2024-03-23Updated: 2024-02-23

Phase 2

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

Active, not recruitingNCT07054034

Shanghai Mabgeek Biotech.Co.LtdBronchial Asthma

Start: 2025-05-11End: 2027-05-26Target: 160Updated: 2025-07-08

Related Papers

Safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of MG-ZG122, a long-acting humanized anti-thymic stromal lymphopoietin mAb, in healthy Chinese: a randomized, double-blind, placebo-controlled, dose-escalation, phase I study.

2025-10-30